You’ve seen many patients face financial hurdles during treatment. Our nonprofit advocacy partners provide alternative savings options to help eligible patients pay for (and move forward with) their treatment plans.
Through collaborations and partnerships with other industry leaders, we’ve dedicated ourselves to fertility advocacy and financial assistance to help make a difference in patients’ lives. The following organizations provide loans, grants, or scholarships that can help your eligible patients manage the cost of treatment when growing their family.*
LIVESTRONG helps men and women diagnosed during their reproductive years understand cancer-related risks to fertility. They also provide eligible patients with access to discounted fertility preservation services and free EMD Serono medication.
Learn more about LIVESTRONG Fertility
†EMD Serono has no control over eligibility or qualifications. EMD Serono's sole responsibility and involvement with respect to the LIVESTRONG Fertility Network is limited to the donation of fertility medications.
To empower Black women to take charge of their fertility and reproductive health, Fertility for Colored Girls offers education, awareness, support, and encouragement to Black women, Black couples, and other women of color who are experiencing infertility and seeking to build a family.
The organization also provides grants through yearly fundraisers to support patients going through IVF treatment.
Learn more about Fertility for Colored Girls
RESOLVE promotes reproductive health and equal access to all family-building options for men and women experiencing infertility or other reproductive disorders. They also provide financial guidance for treatment.
The Cade Foundation provides educational programs on pathways to parenthood, as well as grants to help families with the cost of adoption and fertility treatment.
INCIID (pronounced “inside”) helps individuals and couples explore their family-building options. They also provide grants for IVF treatment through a series of yearly fundraising events.
This leader in education and financial assistance helps men start families through gestational surrogacy.
With a focus on creating awareness through support in the fertility community, Baby Quest provides financial assistance through fertility grants to those who cannot afford the high cost of advanced procedures such as IVF, gestational surrogacy, egg and sperm donation, egg freezing, artificial insemination, and embryo donation.
The Bundle of Joy Fund advocates for infertility education and awareness, and offers financial assistance for IVF treatment to those struggling to conceive a child through the REACH Clinic of Charlotte.
HelpCureHD is on a mission to prevent the gene that causes Huntington’s Disease, a hereditary brain disorder, from being passed on to future generations. They provide monetary assistance to close the financial gap that stands between some couples and preimplantation genetic testing for monogenic/single gene defects (PGT-M IVF), the only option available that guarantees a biological child is HD-free
Support doesn’t always have to be financial. We also collaborate with organizations that assist fertility and family-building through other efforts.
An advocate for LGBTQ+ families and those who wish to form them, Family Equality Council focuses on advancing legal and lived equality by building community, changing hearts and minds, and driving policy change.
Comprised of leading experts in the field, The Alliance is on a mission to increase information, resources, and access to fertility preservation for cancer patients and the healthcare professionals who treat them.
Pregnantish helps people with infertility navigate the emotional, personal, and practical realities of an often-overwhelming process. Their mission is to inspire, educate, and connect the millions of women and men who are starting their families.
These links are provided solely as a convenience to you and not as an endorsement by EMD Serono of the content on such third-party web sites.
Terms and conditions for qualifications are determined solely by each of our advocacy partners individually. Eligibility details can be found on each of our advocacy partners website. EMD Serono has no control over eligibility or qualifications.
Summary of Contraindications Gonal-f® (follitropin alfa injection) RFF* Redi-ject® and Gonal-f® (follitropin alfa for injection) Multi-Dose are contraindicated in patients with prior hypersensitivity to r-hFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin. Please scroll for full IMPORTANT RISK INFORMATION for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and click here for full Prescribing Information for each individual product. RFF : Revised Formulation Female
Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection) Contraindications: GONAL-F® Multi-Dose is contraindicated in women and men who exhibit:
GONAL-F Multi-Dose is also contraindicated in women who exhibit:
WARNINGS Overstimulation of the Ovary During FSH Therapy: Ovarian Torsion Abnormal Ovarian Enlargement Multi-fetal Gestation and Birth Embryofetal toxicity Ectopic Pregnancy Spontaneous Abortion Ovarian Neoplasms Laboratory Tests In most instances, treatment of women with GONAL-F Multi-Dose will result only in follicular recruitment and development. In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the woman indicates that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the OHSS and multiple gestation. ADVERSE REACTIONS Men - There was one serious adverse reaction of gynecomastia requiring surgical excision of breast tissue in a 50-year-old man who received 9 months of therapy with GONAL-F Multi-Dose. Pathology report showed gynecomastia with no atypia. Adverse reactions reported in ≥ 2 patients were acne, injection site pain, gynecomastia, seborrhea, fatigue and libido decreased. Specific Populations: Pregnancy: GONAL-F Multi-Dose is not indicated in pregnant women. There is no human data that the use of gonadotropins (including GONAL-F Multi-Dose) alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations.
Lactation: There are no data on the presence of GONAL-F Multi-Dose in human milk, the effects on the breastfed infant, or the effects on milk production. Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL-F Multi-Dose.
Females and Males of Reproductive Potential: Because GONAL-F Multi-Dose is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F Multi-Dose to a woman
Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Safety and effectiveness of GONAL-F Multi-Dose in postmenopausal women have not been established and it is not indicated in this population.
Patient Counseling: Instruct women and men on the correct usage and dosing of GONAL-F Multi-Dose. Caution against changing the dosage or the schedule of administration unless instructed to do so by a healthcare provider. Prior to beginning therapy with GONAL-F Multi-Dose, inform women and men about the time commitment and monitoring procedures necessary for treatment Inform women and men that if they miss or forget to take a dose of GONAL-F Multi-Dose, they should not double the next dose and should call their healthcare provider for further dosing instructions. For more information, please see the full Prescribing Information and Instructions for Use for GONAL-F Multi-Dose Indications and Usage:
|
Important Risk Information for Cetrotide® (cetrorelix acetate for injection) Cetrotide® is contraindicated in women who are pregnant, are nursing, or have severe renal impairment. Cetrotide® is also contraindicated in women who exhibit or have known hypersensitivity to cetrorelix acetate, mannitol, extrinsic peptide hormone, GnRH or any other GnRH analogs. Treatment with Cetrotide® is not advised in women with severe allergic conditions. Cases of hypersensitivity reactions, including anaphylactoid reactions have been reported. Other adverse events reported include ovarian hyperstimulation syndrome, nausea, headache, and local injection site reactions. Multiple births and congenital abnormalities have been reported. Indication
For complete information, please see full Prescribing information here. |
Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Ovidrel® PreFilled Syringe should only be used by physicians who are experienced with infertility problems, their management and appropriate selection and monitoring of patients. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations, mannitol, or one of their other excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled intracranial lesion, abnormal uterine bleeding of an undetermined origin, an ovarian cyst or enlargement of an undetermined origin. Women who are pregnant or nursing should not use Ovidrel® PreFilled Syringe. Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications. Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported. Indication
For complete information, please see full Prescribing information here. |
Summary of Contraindications Gonal-f® (follitropin alfa injection) RFF* Redi-ject® and Gonal-f® (follitropin alfa for injection) Multi-Dose are contraindicated in patients with prior hypersensitivity to r-hFSH or excipients, high levels of FSH indicating primary gonadal failure, pregnancy, uncontrolled thyroid, adrenal or pituitary disorders, sex hormone dependent tumors of the reproductive tract/accessory organs, tumors of pituitary gland or hypothalamus, abnormal uterine bleeding of undetermined origin and ovarian cyst or enlargement of undetermined origin. Please scroll for full IMPORTANT RISK INFORMATION for Gonal-f® RFF* Redi-ject®, Gonal-f® Multi-Dose and click here for full Prescribing Information for each individual product. RFF : Revised Formulation Female
Important Risk Information for Gonal-f® Multi-Dose (follitropin alfa for injection) Contraindications: GONAL-F® Multi-Dose is contraindicated in women and men who exhibit:
GONAL-F Multi-Dose is also contraindicated in women who exhibit:
WARNINGS Overstimulation of the Ovary During FSH Therapy: Ovarian Torsion Abnormal Ovarian Enlargement Multi-fetal Gestation and Birth Embryofetal toxicity Ectopic Pregnancy Spontaneous Abortion Ovarian Neoplasms Laboratory Tests In most instances, treatment of women with GONAL-F Multi-Dose will result only in follicular recruitment and development. In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the woman indicates that sufficient follicular development has occurred. This may be estimated by ultrasound alone or in combination with measurement of serum estradiol levels. The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the OHSS and multiple gestation. ADVERSE REACTIONS Men - There was one serious adverse reaction of gynecomastia requiring surgical excision of breast tissue in a 50-year-old man who received 9 months of therapy with GONAL-F Multi-Dose. Pathology report showed gynecomastia with no atypia. Adverse reactions reported in ≥ 2 patients were acne, injection site pain, gynecomastia, seborrhea, fatigue and libido decreased. Specific Populations: Pregnancy: GONAL-F Multi-Dose is not indicated in pregnant women. There is no human data that the use of gonadotropins (including GONAL-F Multi-Dose) alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations.
Lactation: There are no data on the presence of GONAL-F Multi-Dose in human milk, the effects on the breastfed infant, or the effects on milk production. Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL-F Multi-Dose.
Females and Males of Reproductive Potential: Because GONAL-F Multi-Dose is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F Multi-Dose to a woman
Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Safety and effectiveness of GONAL-F Multi-Dose in postmenopausal women have not been established and it is not indicated in this population.
Patient Counseling: Instruct women and men on the correct usage and dosing of GONAL-F Multi-Dose. Caution against changing the dosage or the schedule of administration unless instructed to do so by a healthcare provider. Prior to beginning therapy with GONAL-F Multi-Dose, inform women and men about the time commitment and monitoring procedures necessary for treatment Inform women and men that if they miss or forget to take a dose of GONAL-F Multi-Dose, they should not double the next dose and should call their healthcare provider for further dosing instructions. For more information, please see the full Prescribing Information and Instructions for Use for GONAL-F Multi-Dose Indications and Usage:
|
Important Risk Information for Cetrotide® (cetrorelix acetate for injection) Cetrotide® is contraindicated in women who are pregnant, are nursing, or have severe renal impairment. Cetrotide® is also contraindicated in women who exhibit or have known hypersensitivity to cetrorelix acetate, mannitol, extrinsic peptide hormone, GnRH or any other GnRH analogs. Treatment with Cetrotide® is not advised in women with severe allergic conditions. Cases of hypersensitivity reactions, including anaphylactoid reactions have been reported. Other adverse events reported include ovarian hyperstimulation syndrome, nausea, headache, and local injection site reactions. Multiple births and congenital abnormalities have been reported. Indication
For complete information, please see full Prescribing information here. |
Important Risk Information for Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) Ovidrel® PreFilled Syringe should only be used by physicians who are experienced with infertility problems, their management and appropriate selection and monitoring of patients. Ovidrel® PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations, mannitol, or one of their other excipients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, an uncontrolled intracranial lesion, abnormal uterine bleeding of an undetermined origin, an ovarian cyst or enlargement of an undetermined origin. Women who are pregnant or nursing should not use Ovidrel® PreFilled Syringe. Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) and ovarian enlargement with or without pulmonary and vascular complications. Adverse reactions reported include injection site reactions, GI disorders, abdominal pain, nausea, vomiting, ovarian cyst, ovarian hyperstimulation, and thromboembolic events. Multiple births and congenital abnormalities have been reported. Indication
For complete information, please see full Prescribing information here. |